LymphomaNCT04263935
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
An observational study of Lymphoma and Gene Abnormality, run by Henan Cancer Hospital at 1 site in China.
Trial summary
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Lymphoma, Gene Abnormality
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- 3 Jan 2019to 31 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Including demographic characteristics / clinical characteristics / pathological characteristics / treatment and efficacy evaluations.
Who may be able to join
- Diagnosed as lymphoma (according to WHO 2017 classification criteria)
- Life expectancy no less than 3 months
- Agreeing to sign the written informed consents
Who cannot join
- Other malignant tumor history or active malignant tumor need be treated
- Researchers determine unsuited to participate in this trial
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan
Yanyan Liu, M.D. Ph.D, +8613838176375, yyliu@zzu.edu.cn
Yanyan Liu, M.D. Ph.D
About this study
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Read the detailed description
This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.
- Conditions
- Lymphoma, Gene Abnormality
- Keywords
- Lymphoma, Driver Gene Abnormalities, Disease Prognosis
- Medical subject headings
- Lymphoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of driver gene abnormalities
the incidence of driver gene abnormalities by fixed gene testing technology
Measured: from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months
Secondary outcomes (3)
objective response rate
the total proportion of patients with complete response (CR) and partial response (PR)
Measured: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
5-year overall survival
from the date of first patient was included to the date of death by any cause
Measured: from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years
Clinicopathological Characteristics
study data on clinicopathological characteristics related to incidence of driver gene abnormalities
Measured: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2020
- Study start3 Jan 2019
- Primary completion30 Jun 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Henan Cancer Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Yanyan Liu, Henan Cancer Hospital
- Investigators
- Yanyan Liu, M.D. Ph.D, Study director, Henan Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04263935
- Sponsor's protocol ID
- HNCH2019341
- Status last verified
- Apr 2025
- First submitted
- 3 Feb 2020
- Last updated
- 23 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
- ClinicalTrials.gov ID
- NCT04263935
- Acronym / sponsor ID
- HNCH2019341
- Conditions
- Lymphoma, Gene Abnormality
- Keywords
- Lymphoma, Driver Gene Abnormalities, Disease Prognosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Henan Cancer HospitalOther government
- Study start
- 3 Jan 2019 (actual)
- Primary completion
- 30 Jun 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 11 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Detailed description
This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Including demographic characteristics / clinical characteristics / pathological characteristics / treatment and efficacy evaluations.
Key inclusion criteria (3 listed)
- Diagnosed as lymphoma (according to WHO 2017 classification criteria)
- Life expectancy no less than 3 months
- Agreeing to sign the written informed consents
Key exclusion criteria (2 listed)
- Other malignant tumor history or active malignant tumor need be treated
- Researchers determine unsuited to participate in this trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of driver gene abnormalities
Time frame: from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months
the incidence of driver gene abnormalities by fixed gene testing technology
3 secondary outcomes
objective response rate
Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
5-year overall survival
Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years
Clinicopathological Characteristics
Time frame: from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Lymphoma
Not yet recruitingPhase 1/2
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
RecruitingPhase 1
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
B-All, Acute Lymphoblastic Leukemia
RecruitingPhase 2
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, B-All
RecruitingPhase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
RecruitingPhase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yanyan Liu, M.D. Ph.D study director
Henan Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lymphoma and Gene Abnormality, run by Henan Cancer Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yanyan Liu, M.D. Ph.D (+8613818176375, yyliu@zzu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of driver gene abnormalities (time frame: from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2025.